Busch Sørensen M, Sjøstrand H, Sengeløv H, Tiefenthal Thrane M, Juul Holst J, Lyngsøe J
Medical Department C, Bispebjerg Hospital, Copenhagen Denmark.
Eur J Clin Pharmacol. 1991;41(5):401-4. doi: 10.1007/BF00626359.
The effect of a sustained-release verapamil preparation on glucose metabolism was investigated in 10 patients with non-insulin dependent diabetes mellitus. In a single blind cross-over study verapamil 240 mg b.d. for 1 week lowered fasting plasma glucose from a mean value of 11.6 mmol/l to 10.3 mmol.l-1, and the fasting glucose appearance rate was decreased from 1.5 to 1.2 mmol.min-1. The decrease in fasting plasma glucose and glucose appearance rate was not related to the steady state plasma concentration of verapamil, nor-verapamil and the metabolites D.617 and D.620. After oral glucose administration a tendency to lower plasma glucose values was found after verapamil administration. Plasma insulin, C-peptide, total and C-terminal glucagon were not significantly different in the placebo and the verapamil studies, neither in the fasting state nor after glucose. It is concluded that brief verapamil treatment decreases fasting plasma glucose and glucose turn-over in non-insulin dependent diabetics, possibly by inhibition of gluconeogenesis.
对10例非胰岛素依赖型糖尿病患者研究了缓释维拉帕米制剂对葡萄糖代谢的影响。在一项单盲交叉研究中，维拉帕米240毫克，每日两次，服用1周，空腹血浆葡萄糖从平均值11.6毫摩尔/升降至10.3毫摩尔/升，空腹葡萄糖出现率从1.5降至1.2毫摩尔/分钟。空腹血浆葡萄糖和葡萄糖出现率的降低与维拉帕米的稳态血浆浓度、去甲维拉帕米及其代谢产物D.617和D.620无关。口服葡萄糖后，服用维拉帕米后发现有降低血浆葡萄糖值的趋势。在安慰剂和维拉帕米研究中，空腹状态下及葡萄糖负荷后血浆胰岛素、C肽、总胰高血糖素和C端胰高血糖素均无显著差异。结论是，短期维拉帕米治疗可降低非胰岛素依赖型糖尿病患者的空腹血浆葡萄糖和葡萄糖周转率，可能是通过抑制糖异生实现的。
